(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 6 th September 2017
more details on our Transparent Editorial Process, please visit our website: http://emboj.embopress.org/about#Transparent_Process
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
------------------------------------------------REFEREE REPORTS
Referee #1:
This manuscript describes a lot of data that focuses on effects of mammalian Spt5 in pol II transcription. Spt5 is inducibly depleted by 4-HT treatment, and the bulk of the data are from MEFs treated with 4-HT for 72h. The results are interesting and thorough, although of course there are always more experiments to be completed. Although the data generally coincide with findings from other labs, the results here expand existing understanding of this important pol II regulatory factor. Below I point out some areas and experiments that are important to address in a revision.
1. It is important to further verify the depletion of Spt5. At the least, this will require additional information from the authors. Westerns were completed that showed reduced full-length Spt5 protein, and that's good. However, the authors also have RNA-Seq data from the Spt5-depleted cells. Can they confirm that Spt5 mRNA reads were absent/depleted in 4-HT treated cells? Could they map reads to exon 14? I did not see any mention of this. Furthermore, what antibodies were used to detect Spt5 by western? Does the epitope target the deleted region? It is mentioned that antibody information is provided in Table S2 but I could not find Table S2 anywhere among the mansucript materials. Ideally, the authors could probe Spt5 with multiple epitopes to confirm that no truncated products are generated.
2. The recent report about Spt5 depletion in yeast from the Winston lab (Mol Cell 2017 77) is mentioned but I did not see a specific mention of the issue with downstream antisense transcription. The authors should check their GRO-Seq data to see if unexpected antisense transcription is similarly observed upon Spt5 depletion in MEFs. I did not see any mention of this in the current version of the manuscript. As I recall, the Winston group observed widespread antisense transcription upon degron depletion of yeast Spt5 that initiated about 500 bp downstream of the TSS. Of course, the potential location of antisense transcripts may be different in mammalian cells, but is there any evidence at all that within-gene antisense transcription is similarly induced upon Spt5 depletion in MEFs?
3. Related to point 2, the Lis lab (Booth et al. Genome Res. 2016 799) observed global decreases in antisense transcription upon depletion of Spt4 in S. pombe. Similar results are not seen in S. cerevisiae. Once the authors assess antisense transcription from their GRO-Seq data, the authors should comment on this work as well.
4. The Spt5 depletion occurs over a long time frame, 72h. It is important that the authors confirm how/whether global levels of pol II and Spt4 undergo changes during this time frame, using quantitative westerns. Of course, dozens of factors could be tested but these two would be a good start. It is highly plausible that similar reduction in Spt4 will be noted upon Spt5 depletion. In that case, the authors can simply change their description to be reporting on the effects of depletion of the DSIF complex.
5. The Ansari lab reported loss of pol II processivity/premature termination in yeast, upon selective inhibition of Kin28 (Rodriguez-Molina et al. Mol Cell 2016 433) . These results have some similarities with what is shown here in Spt5 depleted cells. Because Spt5 is a putative substrate of Kin28 (Rob Fisher's lab), these results should be mentioned.
Other points 6. Pol II pausing is believed to serve as a checkpoint to enable 5'-capping of the transcript. Given that pausing is reduced in Spt5-depleted cells, do the authors observe changes in mRNA stability? Capping defects? I understand that there are always more experiments to propose and always more work to do, so perhaps all of these questions can remain for future work, but at minimum the authors should acknowledge this and discuss it as one potential manifestation of Spt5 depletion.
7. Can the authors draw any further conclusion from the 15-20kb window downstream of the promoter? Have they attempted to see whether these may correlate with other features, such as long 5'-UTR introns?
8. In describing the flavopiridol (FP) experiments, it is stated that FP "inhibits Ser2 phosphorylation of Pol II by P-TEFb." This is true, but misleading. FP is a pan-kinase inhibitor and treatment of cells with FP will effectively inhibit dozens of kinases (e.g. see Asghar et al. Nat Rev Drug Disc. 2015 130) . This is especially true with 4h treatment at a concentration of 2 µM. This statement should be re-phrased.
Referee #2:
Fitz et al have used a 2-step Flox system to make MEFs that have only very low levels of Spt5 and importantly, Spt5 is depleted from genes. GRO-seq analysis indicates that Spt5 depletion causes a drop in pol II at the TSS and an increase after that at the 5' end of genes, as would be expected. Spt5 depletion causes a promoter-proximal increase in pol II CTD Ser2 phosphorylation. Interestingly, Spt5 depletion causes a transcription elongation decrease only after about 15-20kb and a termination defect, as measured by GRO-seq. This is validated with single gene ChIP and RT-qPCR of premRNA. The authors conclude that Spt5 plays a role at this transition point in continued productive elongation.
Flavopiridol experiments show convincingly that elongation rates are not changed by Spt5 depletion. The authors then conclude that increased intitiation contributes to increases in transcription up to 15kb from the TSS.
I think this is a well thought-out and well executed study and the results are interesting and important Minor point. I'm not sure I really understood the section on elongation rates calculated from nascent and mRNA levels-last paragraph of page 12 to third paragraph of page 14. Perhaps the authors could make this a bit clearer?
Non-essential It would be nice to know what is happening to RNA processing when Spt5 is depleted.
Referee #3:
In the present manuscript, Fitz at al. use genome-scale approaches along with single-gene assays to investigate the role of the highly conserved elongation factor Spt5 during RNA polymerase II (Pol II) transcription in mammalian cells. The authors deplete Spt5 from mouse embryonic fibroblasts using the Cre-loxP system and study the genome-wide consequences on Pol II occupancy, the Pol II CTD phosphorylation state, nascent transcription and total RNA levels. ChIP-seq and GRO-seq analyses reveal a strong decrease of Pol II occupancy at the promoter-proximal regions and an increase over the proximal gene body regions genome-wide. The authors further show by ChIP-seq that the CTD-Ser5P are decreased and CTD-Ser2P levels are increased at the 5'-end of genes upon Spt5 depletion. Furthermore, the authors provide evidence for Pol II occupancy to be strongly decreased at the distal gene body region (>20 kb) of long genes. Since the authors found no evidence for reduced Pol II transcription elongation rates upon Spt5 depletion, the decrease in Pol II occupancy rather reflects a reduction of transcribing Pol II complexes. These observations led to the conclusion that Spt5 is important for the processivity of RNA polymerase transcription >20 kb downstream of the TSS at long mammalian genes.
This study uncovers new interesting aspects of the role of Spt5 during Pol II transcription elongation. The finding that Spt5 is required for processive transcription 20 kb downstream of the TSS at long mammalian genes is a significant result and will be of broad interest for the transcription community. This work will inspire future studies to further characterize the Spt5-dependent proposed processivity checkpoint. However, in its present form the manuscript is in parts hard to read and needs to be improved.
Major comments:
(1) Spt5 is a key elongation factor that closely interacts with many other elongation and termination factors during Pol II transcription, including Spt4 and Paf1. Thus depletion of Spt5 per se will trigger pleiotropic effects. A main weakness of the present study is the long Spt5 depletion time (72 hours). This long treatment time further increases the risk of indirect effects and cellular adjustments, and complicates the assignment of Spt5-specific functions. The authors provide no information on whether other components of the Pol II elongation complex, such as Spt4 and Paf1, are affected upon Spt5 depletion. The author should address these limitations in the main text of this study. Conclusions, such as on page 20 "defined the precise role of Spt5", should be softened accordingly.
(2) The authors conclude on Page 8 that upon Spt5 depletion "Pol II undergoes normal initiation". This is not in line with several observations presented in the manuscript. ChIP-seq analyses clearly show a strong decrease of Pol II and Pol II Ser5P occupancy upon Spt5 depletion around the TSS. This suggests that transcription initiation seems also to be affected when Spt5 is depleted. This should be addressed in the main text and the conclusion needs to be softened. (Fig. 3A) should be characterized in more depth. How many active genes show this transition in Pol II occupancy? What is the exact location (distance to TSS on average) of this transition? How does the location vary between different genes? (4) As mentioned earlier, the manuscript is at parts hard to read and lengthy. For instance, the authors conclude from pages 12 to 14 that Spt5 depletion does not affect Pol II transcription elongation rates. This is then again presented and now in a more convincing way on pages 14 to 16. Both sections (pages 12 to 16) should be combined and at the same time shortened. Minor comments:
(1) Formatting error on Page 2, first paragraph: 5.6-dichloro-1-__-D-ribofuranosylbenzimidazole; similar formatting errors also on page 22
(2) Page 2, second parapgraph: "Promoters initially recruit Pol II to assamble...". This statement is confusing since general transcription factors including TBP recruit Pol II to the promoter region. This statement needs to be changed.
(3) Typo on Page 2, second paragraph: "P-TEFb inhibition leads a genome-wide accumulation..." needs to be replaced by "P-TEFb inhibition leads to a genome-wide accumulation..." (4) Page 2/3 first paragraph: "Importantly, Spt5 remains associated with Pol II until termination...". The original papers need to be cited that support this statement.
(5) Page 5, second paragraph: the correlation coefficients between the replicates need to be added.
(6) Page 8, second paragraph: CTD Ser5P is not a mark of "early initiation", as stated by the authors, but rather of early elongation. This needs to be changed. Figure 3A : an arrow at the 20 kb region right at the transition of the Pol II occupancy would be helpful.
(10) Figure 3B (upper panel) and 6B: Differences between WT and SPT5dep can hardly be seen. Zoom-in views would be helpful.
(11) Table S1 and S2 as stated in the main text are missing.
(12) No ArrayExpress or GEO identifier for the genome-wide data is provided. This manuscript describes a lot of data that focuses on effects of mammalian Spt5 in pol II transcription. Spt5 is inducibly depleted by 4-HT treatment, and the bulk of the data are from MEFs treated with 4-HT for 72h. The results are interesting and thorough, although of course there are always more experiments to be completed. Although the data generally coincide with findings from other labs, the results here expand existing understanding of this important pol II regulatory factor. Below I point out some areas and experiments that are important to address in a revision.
We now show that read mapping to exons 14-16 from mRNAseq, GROseq and ChIPseq data ( Figure  S1E-F 
We now provide a new figure dedicated to antisense transcript analysis (Figure S5). Within gene bodies, there appears to be no clear trend towards up-or down regulation and the location of such changes is also highly varied within the gene (Figure S5A). In the promoter-proximal region (TSS -/+500 bp), we detect global decrease in antisense transcription in the TSS-upstream region (TSS -500 bp; also seen in the metagene plots in Figures 1B and 2A) but no bias towards up-or downregulation in the TSS-downstream region (TSS + 500 bp; Figure S5C-D). This suggests that the role of Spt5 in regulating antisense transcription may differ between mammalian cells and yeast.
As requested, we have commented on this in the Discussion.
4. The Spt5 depletion occurs over a long time frame, 72h. It is important that the authors confirm how/whether global levels of pol II and Spt4 undergo changes during this time frame, using quantitative westerns. Of course, dozens of factors could be tested but these two would be a good start. It is highly plausible that similar reduction in Spt4 will be noted upon Spt5 depletion. In that case, the authors can simply change their description to be reporting on the effects of depletion of the DSIF complex. Figure S3A-B) . Other points 6. Pol II pausing is believed to serve as a checkpoint to enable 5'-capping of the transcript. Given that pausing is reduced in Spt5-depleted cells, do the authors observe changes in mRNA stability? Capping defects? I understand that there are always more experiments to propose and always more work to do, so perhaps all of these questions can remain for future work, but at minimum the authors should acknowledge this and discuss it as one potential manifestation of Spt5 depletion. . This is especially true with 4h treatment at a concentration of 2 µM. This statement should be re-phrased.
Thank you for pointing this out. We have re-phrased this sentence.
Referee #2:
I think this is a well thought-out and well executed study and the results are interesting and important
Minor point. I'm not sure I really understood the section on elongation rates calculated from nascent and mRNA levels-last paragraph of page 12 to third paragraph of page 14. Perhaps the authors could make this a bit clearer?
We Figure  5A ). However, we cannot rule out that some mRNAs will be subjected to Spt5-mediated processing and we are currently investigating this as a follow-up project.
Referee #3:
Major comments:
We have performed protein analysis of Spt4, Paf1, Spt16 (FACT) (2) The authors conclude on Page 8 that upon Spt5 depletion "Pol II undergoes normal initiation". This is not in line with several observations presented in the manuscript. ChIP-seq analyses clearly show a strong decrease of Pol II and Pol II Ser5P occupancy upon Spt5 depletion around the TSS. This suggests that transcription initiation seems also to be affected when Spt5 is depleted. This should be addressed in the main text and the conclusion needs to be softened. Figure  3C -D. As seen in Figure 3C , the average Spt5 dep /WT ratio clearly decreases between ~13 kb and 23 kb from the TSS (the region within the gene used for this analysis), and this is observed at 70% of genes >50 kb in length. However, there is considerable variation (spikiness) in the signal in this region making it difficult to assign an exact location for the transition, although we assign an average value of ~17 kb ( Figure 3C ). The variation most likely arises from the fact that the signal decreases gradually rather than at a single point, and that the change is not uniform at all points between different genes. For this reason, we called it a transition zone occurring between 15-20 kb from the TSS.
(4) As mentioned earlier, the manuscript is at parts hard to read and lengthy. For instance, the authors conclude from pages 12 to 14 that Spt5 depletion does not affect Pol II transcription elongation rates. This is then again presented and now in a more convincing way on pages 14 to 16. Both sections (pages 12 to 16) should be combined and at the same time shortened.
We agree with reviewer and we have both shortened and combined this section of the results. We hope the revised version is clearer. In contrast, the fold-changes in gene bodies are more comparable between these assays (as seen in Figure 2A) 
It is true that there is not an absolute correlation in the metagene analysis between the fold-change in

This has now been included.
(6) Page 8, second paragraph: CTD Ser5P is not a mark of "early initiation", as stated by the authors, but rather of early elongation. This needs to be changed. Figure 3D ). This analysis shows that beyond the transition point, the fold-changes in Pol II remain relatively unchanged up to the TTS. This sentence has been modified to include average gene lengths. (9) Figure 3A : an arrow at the 20 kb region right at the transition of the Pol II occupancy would be helpful.
We have done as requested. (10) Figure 3B (upper panel) and 6B: Differences between WT and SPT5dep can hardly be seen. Zoom-in views would be helpful. Figure 3B and 6B. We note that the Chd2 gene in Figure 6B overlaps Thank you for submitting a revised version of your manuscript to The EMBO Journal. It has now been seen by two of the original referees and their comments are shown below.
We have done as requested. The zoom-in views are presented as insets in
As you will see, the referees both find that all major criticisms have been sufficiently addressed and they recommend the manuscript for publication, pending a few minor clarifications. I would therefore like to invite you to submit a final revision of the study in which you clarify/elaborate on these few remaining points.
Thank you again for giving us the chance to consider your manuscript for The EMBO Journal, I look forward to receiving your final revision.
I am happy with the revisions and comments and clarifications made by the authors. I just have a few additional suggestions that I think the authors could use to improve the final version.
1. In EV Figure 1G , it appears that the order of the lanes are switched for the Spt5 blots on the left side of the image. Strange, but the trend for WT Spt5 is the opposite of that seen for the control, histone H3.
2. In EV Figure 4 and elsewhere, it is still very hard to visualize any changes in GRO-Seq reads or RNAPII occupancy in the gene bodies, because the signal is so small due to the scale being defined by the TSS region. In a few places a magnified image is shown and perhaps this can be done throughout.
The authors have addressed all of my concerns. Most notably, Fitz et al. performed additional experiments to show that protein levels of other integral subunits of the Pol II transcription elongation complex, including the levels of the SPT5 interactor SPT4 and PAF1, are not significantly changed upon SPT5 depletion (Fig. EV3 ). This suggests that indirect effects that may arise from the SPT5 depletion are minimal and that the observed transcriptional changes are most likely SPT5-specific. Furthermore, the authors performed addtional bioinformatics analyses to reveal more interesting details regarding the transition of Pol II occupancy upon SPT5 depletion (Fig. 3 C,D) . For instance, the authors now show that SPT5 is required for processive transcription elongation at the majority (70%) of long genes.
The authors now also added the supplementary tables (EV1: deep sequencing statistics; EV2: qPCR primer sequences; EV3: information on antibodies) and provide a GEO identifier for the genomewide data.
Overall, I feel that the additional analyses and clarifications by Fitz et al. have strongly improved the manuscript.
2nd Revision -authors' response 10 th January 2018
We thank the reviewers for their positive comments on the revision of our manuscript. Below, we have addressed the additional comments and suggestions.
1. In EV Figure 1G , it appears that the order of the lanes are switched for the Spt5 blots on the left side of the image. Strange, but the trend for WT Spt5 is the opposite of that seen for the control, histone H3. 2. In EV Figure 4 and elsewhere, it is still very hard to visualize any changes in GRO-Seq reads or RNAPII occupancy in the gene bodies, because the signal is so small due to the scale being defined by the TSS region. In a few places a magnified image is shown and perhaps this can be done throughout.
We have now shown magnified images throughout.
